189 related articles for article (PubMed ID: 17071474)
1. NY-ESO-1 immunotherapy for multiple myeloma.
Szmania S; Tricot G; van Rhee F
Leuk Lymphoma; 2006 Oct; 47(10):2037-48. PubMed ID: 17071474
[TBL] [Abstract][Full Text] [Related]
2. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
Batchu RB; Moreno AM; Szmania SM; Bennett G; Spagnoli GC; Ponnazhagan S; Barlogie B; Tricot G; van Rhee F
Cancer Res; 2005 Nov; 65(21):10041-9. PubMed ID: 16267030
[TBL] [Abstract][Full Text] [Related]
3. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
4. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
van Rhee F; Szmania SM; Zhan F; Gupta SK; Pomtree M; Lin P; Batchu RB; Moreno A; Spagnoli G; Shaughnessy J; Tricot G
Blood; 2005 May; 105(10):3939-44. PubMed ID: 15671442
[TBL] [Abstract][Full Text] [Related]
5. [NY-ESO-1 and cancer immunotherapy].
Peng JR; Leng XS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):371-7. PubMed ID: 18795604
[TBL] [Abstract][Full Text] [Related]
6. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.
Atanackovic D; Arfsten J; Cao Y; Gnjatic S; Schnieders F; Bartels K; Schilling G; Faltz C; Wolschke C; Dierlamm J; Ritter G; Eiermann T; Hossfeld DK; Zander AR; Jungbluth AA; Old LJ; Bokemeyer C; Kröger N
Blood; 2007 Feb; 109(3):1103-12. PubMed ID: 17023585
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy.
de Carvalho F; Vettore AL; Inaoka RJ; Karia B; Andrade VC; Gnjatic S; Jungbluth AA; Colleoni GW
Cancer Immun; 2011 Jan; 11():1. PubMed ID: 21247062
[TBL] [Abstract][Full Text] [Related]
8. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
Schuberth PC; Jakka G; Jensen SM; Wadle A; Gautschi F; Haley D; Haile S; Mischo A; Held G; Thiel M; Tinguely M; Bifulco CB; Fox BA; Renner C; Petrausch U
Gene Ther; 2013 Apr; 20(4):386-95. PubMed ID: 22739387
[TBL] [Abstract][Full Text] [Related]
9. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.
Karbach J; Gnjatic S; Bender A; Neumann A; Weidmann E; Yuan J; Ferrara CA; Hoffmann E; Old LJ; Altorki NK; Jäger E
Int J Cancer; 2010 Feb; 126(4):909-18. PubMed ID: 19728336
[TBL] [Abstract][Full Text] [Related]
10. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
Szender JB; Papanicolau-Sengos A; Eng KH; Miliotto AJ; Lugade AA; Gnjatic S; Matsuzaki J; Morrison CD; Odunsi K
Gynecol Oncol; 2017 Jun; 145(3):420-425. PubMed ID: 28392127
[TBL] [Abstract][Full Text] [Related]
11. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
[TBL] [Abstract][Full Text] [Related]
12. NY-ESO-1: review of an immunogenic tumor antigen.
Gnjatic S; Nishikawa H; Jungbluth AA; Güre AO; Ritter G; Jäger E; Knuth A; Chen YT; Old LJ
Adv Cancer Res; 2006; 95():1-30. PubMed ID: 16860654
[TBL] [Abstract][Full Text] [Related]
13. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.
Jakka G; Schuberth PC; Thiel M; Held G; Stenner F; Van Den Broek M; Renner C; Mischo A; Petrausch U
Anticancer Res; 2013 Oct; 33(10):4189-201. PubMed ID: 24122982
[TBL] [Abstract][Full Text] [Related]
14. NY-ESO-1 protein expression and humoral immune responses in prostate cancer.
Fosså A; Berner A; Fosså SD; Hernes E; Gaudernack G; Smeland EB
Prostate; 2004 Jun; 59(4):440-7. PubMed ID: 15065093
[TBL] [Abstract][Full Text] [Related]
15. NY-ESO-1 expression in meningioma suggests a rationale for new immunotherapeutic approaches.
Baia GS; Caballero OL; Ho JS; Zhao Q; Cohen T; Binder ZA; Salmasi V; Gallia GL; Quinones-Hinojosa A; Olivi A; Brem H; Burger P; Strausberg RL; Simpson AJ; Eberhart CG; Riggins GJ
Cancer Immunol Res; 2013 Nov; 1(5):296-302. PubMed ID: 24777967
[TBL] [Abstract][Full Text] [Related]
16. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.
Nishikawa H; Sato E; Briones G; Chen LM; Matsuo M; Nagata Y; Ritter G; Jäger E; Nomura H; Kondo S; Tawara I; Kato T; Shiku H; Old LJ; Galán JE; Gnjatic S
J Clin Invest; 2006 Jul; 116(7):1946-54. PubMed ID: 16794737
[TBL] [Abstract][Full Text] [Related]
17. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.
Iura K; Kohashi K; Ishii T; Maekawa A; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Matsumoto Y; Iwamoto Y; Oda Y
Virchows Arch; 2017 Sep; 471(3):383-392. PubMed ID: 28744588
[TBL] [Abstract][Full Text] [Related]
18. Plasma cell lysate as an antigen source in multiple myeloma immunotherapy.
Ritchie DS
Leuk Lymphoma; 2007 Oct; 48(10):1894-5. PubMed ID: 17917956
[No Abstract] [Full Text] [Related]
19. [Targeting cancer antigen (MAGE-A4, NY-ESO -1) for immunotherapy].
Imai N; Ikeda H; Shiku H
Nihon Rinsho; 2012 Dec; 70(12):2125-9. PubMed ID: 23259384
[TBL] [Abstract][Full Text] [Related]
20. Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.
Klippel ZK; Chou J; Towlerton AM; Voong LN; Robbins P; Bensinger WI; Warren EH
Gene Ther; 2014 Mar; 21(3):337-42. PubMed ID: 24451117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]